Glucocorticoid Receptor Suppresses Tumor Formation by Ensuring Accurate Chromosome Segregation During Mitosis
|
By LabMedica International staff writers Posted on 20 Apr 2015 |

Image: Electrophoretic data confirmed disruption of mitosis in cells lacking GR (Photo courtesy of the University of Manchester).
A team of British molecular biologists has defined the mechanism by which glucocorticoid receptor (GR) regulates the process of mitosis to prevent errors in cell division that could lead to tumor formation.
GR is a member of the nuclear receptor superfamily, which controls programs regulating cell proliferation, differentiation, and apoptosis. GR is expressed in almost every cell in the body and regulates genes controlling development, metabolism, and immune response. As the receptor gene is expressed in several forms, it has many different effects in various parts of the body. Unbound receptor resides in the cytosol of the cell. Binding of GR to glucocorticoids triggers its primary mechanism of action, which is the regulation of gene transcription. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol (by preventing the translocation of other transcription factors from the cytosol into the nucleus).
Investigators at the University of Manchester (United Kingdom) identified an additional role for GR related to regulation of cell division. They discovered that specifically modified GR species accumulated at the mitotic spindle during mitosis in a distribution that overlapped with enzymes of the Aurora kinase family. They found that Aurora A was required to mediate mitosis-driven GR phosphorylation, but not recruitment of GR to the spindle. GR was necessary for mitotic progression, with increased time to complete mitosis, frequency of mitotic aberrations, and death in mitosis observed following GR knockdown. Complementation studies revealed an essential role for the GR ligand-binding domain, but no clear requirement for ligand binding in regulating chromosome segregation.
GR haploinsufficient mice (animals with only a single functional copy of the GR gene that did not produce enough of the gene product to bring about the wild-type condition) had an increased incidence of tumor formation, and these tumors were further depleted for GR, implying additional GR loss as a consequence of cell transformation. Reduced GR expression was identified in a panel of human liver, lung, prostate, colon, and breast cancers.
The unexpected role for the GR in promoting accurate chromosome segregation during mitosis marked GR as an authentic tumor suppressor gene. "Cancer is caused by cell division going wrong, but no one has previously looked at the role GR has to play in this process," said senior author Dr. David Ray, professor of human development at the University of Manchester. "It is now clear that it is vital."
The study was published in the April 6, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Manchester
GR is a member of the nuclear receptor superfamily, which controls programs regulating cell proliferation, differentiation, and apoptosis. GR is expressed in almost every cell in the body and regulates genes controlling development, metabolism, and immune response. As the receptor gene is expressed in several forms, it has many different effects in various parts of the body. Unbound receptor resides in the cytosol of the cell. Binding of GR to glucocorticoids triggers its primary mechanism of action, which is the regulation of gene transcription. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol (by preventing the translocation of other transcription factors from the cytosol into the nucleus).
Investigators at the University of Manchester (United Kingdom) identified an additional role for GR related to regulation of cell division. They discovered that specifically modified GR species accumulated at the mitotic spindle during mitosis in a distribution that overlapped with enzymes of the Aurora kinase family. They found that Aurora A was required to mediate mitosis-driven GR phosphorylation, but not recruitment of GR to the spindle. GR was necessary for mitotic progression, with increased time to complete mitosis, frequency of mitotic aberrations, and death in mitosis observed following GR knockdown. Complementation studies revealed an essential role for the GR ligand-binding domain, but no clear requirement for ligand binding in regulating chromosome segregation.
GR haploinsufficient mice (animals with only a single functional copy of the GR gene that did not produce enough of the gene product to bring about the wild-type condition) had an increased incidence of tumor formation, and these tumors were further depleted for GR, implying additional GR loss as a consequence of cell transformation. Reduced GR expression was identified in a panel of human liver, lung, prostate, colon, and breast cancers.
The unexpected role for the GR in promoting accurate chromosome segregation during mitosis marked GR as an authentic tumor suppressor gene. "Cancer is caused by cell division going wrong, but no one has previously looked at the role GR has to play in this process," said senior author Dr. David Ray, professor of human development at the University of Manchester. "It is now clear that it is vital."
The study was published in the April 6, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Manchester
Latest BioResearch News
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreMolecular Diagnostics
view channel
Genomic Assays Predict Anthracycline Benefit in Early-Stage Breast Cancer
Anthracycline-based chemotherapy remains a cornerstone of treatment for early-stage, hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer, but its risks of cardiotoxicity... Read more
Gene Expression Test Refines Melanoma Biopsy Decision-Making
Sentinel lymph node biopsy (SLNB) is central to melanoma staging, yet most procedures are negative and some patients experience surgery-related complications. Clinicians need decision-support tools that... Read more
Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
Minimal residual disease testing is increasingly used to guide adjuvant therapy and surveillance in solid tumors, but detecting very low levels of circulating tumor DNA remains challenging in routine practice.... Read more
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read more
New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease
Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. In primary Sjögren disease, inflammation of salivary and lacrimal glands leads... Read moreMicrobiology
view channel
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read more
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








